Alvotech And Teva Follow Amgen With US Stelara Settlement

Pair Gain 21 February 2025 Launch Date For AVT04 Ustekinumab Biosimilar

 
• By Dave Wallace

Teva and Alvotech have struck a deal with Stelara originator Johnson & Johnson to secure a 21 February 2025 launch date for their AVT04 ustekinumab biosimilar in the US – just over seven weeks after rival Amgen is able to enter the market.

Desk calendar showing February 2025
Teva and Alvotech have a launch date no later than 21 February 2025 • Source: Shutterstock

More from Biosimilars

More from Products